Implied Volatility Surging for Akebia Therapeutics Stock Options
Investors need to pay close attention to AKBA stock based on the movements in the options market lately.
Theravance's Q3 Earnings Surpass Estimates, Revenues Match
TBPH delivers a third-quarter profit, beating estimates, and 19% revenue growth, fueled by rising collaboration income from Viatris related to Yupelri sales.
Akebia Therapeutics ( AKBA ) Loses 39.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Akebia Therapeutics (AKBA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend ...
Mettler-Toledo Q3 Earnings Top Estimates, Sales Decline Y/Y
MTD posted stronger-than-expected Q3 results, lifted by segment growth and solid guidance for 2025 and 2026.
Globus Medical ( GMED ) Tops Q3 Earnings and Revenue Estimates
Globus Medical (GMED) delivered earnings and revenue surprises of +49.37% and +4.85%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Vafseo® ( vadadustat ) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs - Akebia Therapeutics ( NASDAQ:AKBA )
CAMBRIDGE, Mass., Nov. 06, 2025 ( GLOBE NEWSWIRE ) -- Akebia Therapeutics®, Inc. ( NASDAQ:AKBA ) , a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the presentation of a post-hoc win odds analysis of all-cause mortality and ...
Vafseo® ( vadadustat ) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs
Win-Odds Analysis Presented at American Society of Nephrology Kidney Week 2025 Win-Odds Analysis Presented at American Society of Nephrology Kidney Week ...
Zevra Therapeutics ( ZVRA ) Reports Q3 Loss, Lags Revenue Estimates
Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of +75.00% and -1.77%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Top 3 Health Care Stocks Which Could Rescue Your Portfolio In November - Acadia Healthcare Co ( NASDAQ:ACHC ) , Akebia Therapeutics ( NASDAQ:AKBA )
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
Why Is Akebia Therapeutics Stock Plunging Today - Akebia Therapeutics ( NASDAQ:AKBA )
Akebia Therapeutics Inc. ( NASDAQ:AKBA ) stock is trading lower on Wednesday. The kidney disease company met with the U.S.
Mondelez International, Stride, Varonis Systems And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Akebia Therapeutics ( NASDAQ:AKBA ) , Caesars Entertainment ( NASDAQ:CZR )
U.S. stock futures were mixed this morning, with the Dow futures falling around 100 points on Wednesday. Shares of Mondelez International Inc ( NASDAQ:MDLZ ) fell sharply in pre-market trading after the company lowered its FY2025 earnings guidance.
Why Teradyne Shares Are Trading Higher By More Than 20%; Here Are 20 Stocks Moving Premarket - Bloom Energy ( NYSE:BE ) , Akebia Therapeutics ( NASDAQ:AKBA )
Shares of Teradyne Inc ( NASDAQ:TER ) rose sharply in today's pre-market trading after the company announced better-than-expected third-quarter results and issued strong forecast for the current quarter. Teradyne reported quarterly earnings of 85 cents per share which beat the analyst ...
Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients - Akebia Therapeutics ( NASDAQ:AKBA )
CAMBRIDGE, Mass., Oct. 28, 2025 ( GLOBE NEWSWIRE ) -- Akebia Therapeutics®, Inc. ( NASDAQ:AKBA ) , a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that after meeting with the U.S.
Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025 - Akebia Therapeutics ( NASDAQ:AKBA )
CAMBRIDGE, Mass., Oct. 20, 2025 ( GLOBE NEWSWIRE ) -- Akebia Therapeutics®, Inc. ( NASDAQ:AKBA ) , a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the American Society of Nephrology Kidney Week ...
Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025
Presentations Detail Ongoing Vafseo® ( Vadadustat ) Real-World Studies and Explore Insights Regarding Clinical Benefits and Dosing of Vafseo Presentations Detail Ongoing Vafseo® ( Vadadustat ) Real-World Studies and Explore Insights Regarding Clinical Benefits and Dosing of ...
Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics
Small-cap biotech momentum surges as AKBA, IRWD, PYXS, CRDL, and PSTV gain on pipeline progress and sector recovery.
5 Small Drug Stocks to Buy as the Industry Shows Some Recovery
Innovation is at its peak in the Zacks Medical-Drugs industry. AKBA, IRWD, PYXS, CRDL and PSTV may prove to be good additions to one's portfolio.
Is Intellia Therapeutics ( NTLA ) Outperforming Other Medical Stocks This Year?
Here is how Intellia Therapeutics, Inc. (NTLA) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.
Karyopharm Therapeutics ( KPTI ) Moves 27.9% Higher: Will This Strength Last?
Karyopharm Therapeutics (KPTI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Akebia Therapeutics to Present at Upcoming Investor Conferences - Akebia Therapeutics ( NASDAQ:AKBA )
CAMBRIDGE, Mass., Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- Akebia Therapeutics®, Inc. AKBA, a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that its executives will participate in two investor conferences in September: Wells Fargo ...
Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® ( vadadustat ) Across All IRC Dialysis Clinics - Akebia Therapeutics ( NASDAQ:AKBA )
CAMBRIDGE, Mass. and FRANKLIN, Tenn., Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Akebia Therapeutics®, Inc.
Akebia ( AKBA ) Q2 Revenue Jumps 43%
Akebia Therapeutics ( NASDAQ:AKBA ) , a biopharmaceutical company specializing in kidney disease treatments, reported its earnings on August 7, 2025, covering results for the quarter. The headline news was a marked upturn in revenue and a transition to positive GAAP net income.
Akebia Therapeutics ( AKBA ) Reports Break-Even Earnings for Q2
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of +100.00% and +33.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
OmniAb, Inc. ( OABI ) Reports Q2 Loss, Lags Revenue Estimates
OmniAb, Inc. (OABI) delivered earnings and revenue surprises of -7.14% and -35.71%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Akebia Initiates Vafseo® ( vadadustat ) Post-Marketing Study in Conjunction with Large Dialysis Organization - Akebia Therapeutics ( NASDAQ:AKBA )
CAMBRIDGE, Mass., Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- Akebia Therapeutics®, Inc. AKBA, a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the initiation of a post-marketing study to identify additional potential benefits of ...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
CAMBRIDGE, Mass., Aug. 01, 2025 ( GLOBE NEWSWIRE ) -- Akebia Therapeutics®, Inc. ( Nasdaq: AKBA ) , a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an aggregate of 238,500 shares of ...
Are Medical Stocks Lagging Akebia Therapeutics ( AKBA ) This Year?
Here is how Akebia Therapeutics (AKBA) and Alignment Healthcare (ALHC) have performed compared to their sector so far this year.
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer - Vor Biopharma ( NASDAQ:VOR )
Dr. Zuraw led clinical development of telitacicept across MG, Sjögren's, SLE, and RA at RemeGen, resulting in multiple regulatory approvals in China; brings deep U.S. and global development experience to support Vor Bio's new development focus and execution of late-stage programs
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer
CAMBRIDGE, Mass., July 17, 2025 ( GLOBE NEWSWIRE ) -- Vor Bio ( Nasdaq: VOR ) , a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Qing Zuraw, M.D., M.P.H., M.B.A., as Chief Development Officer, effective immediately.
Akebia Therapeutics ( AKBA ) Upgraded to Strong Buy: Here's What You Should Know
Akebia Therapeutics (AKBA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Akebia Therapeutics ( AKBA ) Stock Outpacing Its Medical Peers This Year?
Here is how Akebia Therapeutics (AKBA) and ResMed (RMD) have performed compared to their sector so far this year.
Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference
CAMBRIDGE, Mass., July 08, 2025 ( GLOBE NEWSWIRE ) -- Akebia Therapeutics®, Inc. ( Nasdaq: AKBA ) , a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Nik Grund, Chief Commercial Officer, will participate in a Fireside Chat ...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Akebia Therapeutics ( NASDAQ:AKBA )
CAMBRIDGE, Mass., July 01, 2025 ( GLOBE NEWSWIRE ) -- Akebia Therapeutics®, Inc. AKBA, a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an aggregate of 141,800 shares of Akebia's common ...
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors - Avalo Therapeutics ( NASDAQ:AVTX )
WAYNE, Pa., June 18, 2025 ( GLOBE NEWSWIRE ) -- Avalo Therapeutics, Inc. AVTX, a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita Jain, M.D. to its Board of Directors.
Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology
Akebia continues to publish important, clinically relevant data to further physicians' understanding of Vafseo® ( vadadustat ) Akebia continues to publish important, clinically relevant data to further physicians' understanding of ...
Akebia Therapeutics ( AKBA ) Q1 Earnings and Revenues Top Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 200% and 26.83%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Xencor ( XNCR ) Reports Q1 Loss, Tops Revenue Estimates
Xencor (XNCR) delivered earnings and revenue surprises of -4.76% and 48.38%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Akebia Therapeutics ( AKBA ) Expected to Beat Earnings Estimates: Should You Buy?
Akebia Therapeutics (AKBA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why You Shouldn't Bet Against Akebia Therapeutics ( AKBA ) Stock
Akebia Therapeutics (AKBA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering
AKBA's shares fell after announcing the pricing of its secondary issue of shares, which were at a discount to the previous closing price.
Crude Oil Gains Over 1%; US Weekly Jobless Claims Increase - Benson Hill ( NASDAQ:BHIL ) , Akebia Therapeutics ( NASDAQ:AKBA )
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Thursday. The Dow traded up 0.63% to 42,230.78 while the NASDAQ climbed 0.81% to 17,894.89. The S&P 500 also rose, gaining, 0.61% to 5,710.13. Communication services shares rose by 1.4% on ...
JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Akebia Therapeutics ( NASDAQ:AKBA ) , Enerflex ( NYSE:EFXT )
U.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Thursday. Shares of JOYY Inc. YY fell sharply in today's pre-market trading following weak quarterly sales. JOYY reported quarterly earnings of $1.77 per share which beat the analyst consensus estimate ...
Akebia Therapeutics Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass., March 19, 2025 ( GLOBE NEWSWIRE ) -- Akebia Therapeutics®, Inc. ( "Akebia" ) ( Nasdaq: AKBA ) , a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the pricing of its underwritten public offering ( the ...
Akebia Therapeutics Announces Proposed Public Offering of Common Stock - Akebia Therapeutics ( NASDAQ:AKBA )
CAMBRIDGE, Mass., March 19, 2025 ( GLOBE NEWSWIRE ) -- Akebia Therapeutics®, Inc. ( "Akebia" ) AKBA, a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has commenced an underwritten public offering ( the "Offering" ) .
Hallador Energy, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Akebia Therapeutics ( NASDAQ:AKBA ) , Arlo Technologies ( NYSE:ARLO )
U.S. stock futures were lower this morning, with the Dow futures falling around 0.1% on Tuesday. Shares of Hallador Energy Company HNRG fell sharply in today's pre-market trading following a fourth-quarter sales miss.
Akebia Therapeutics ( AKBA ) Reports Q4 Loss, Tops Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -25% and 18.21%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for January 3rd
AKBA, KOF and GES have been added to the Zacks Rank #24 (Strong Sell) List on January 3, 2024.
New Strong Sell Stocks for December 5th
AKBA, KOF and XRAY have been added to the Zacks Rank #5 (Strong Sell) List on December 5, 2024.
New Strong Sell Stocks for November 22nd
ATI, AKBA and ALTG have been added to the Zacks Rank #5 (Strong Sell) List on November 22, 2024.
Akebia Therapeutics ( AKBA ) Reports Q3 Loss, Misses Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -100% and 18.03%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
